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Abstract 
Background: Influenza virus is the major cause of lower respiratory tract illnesses on the worldwide. 
Vaccination can be an effective tool to prevent its outbreak. Highly conserved viral nucleoprotein is an 
effective vaccine candidate to provide heterosubtypic immunity, offering resistance against various influenza 
virus strains. 
Materials and Methods: In present research NP gene was inserted in pET-22b expression vector. New 
construct (pET-22b/NP) was transformed into E. coli BL21 (DE3) strain and the expression of nucleoprotein 
was induced by IPTG. It was analyzed by SDS-PAGE and confirmed by Western blotting. 
Results: Western blotting confirmed the expression and production of recombinant Influenza nucleoprotein. 
Conclusion: These results suggest that the codon-optimized influenza A virus NP gene can be efficiently 
expressed in E. coli. 
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It is well known that influenza infections cause 
severe illness in 3–5 million people worldwide and 
kill 250,000–500,000 humans each year. Despite the 
currently influenza vaccines are against subtype-
specific virus and produce neutralizing antibodies, 
there are still significant deficiencies, because the 
designed vaccines cannot protect against new 
subtypes or antigenic variants
1
. 
Influenza A nucleoprotein (NP), the protein 
component of ribonucleoprotein (RNP) complexes, is 
also relatively conserved that make it an appropriate 
candidate for an efficient influenza vaccine. Its real 
function is the protection of single strand RNA 
genome of influenza virus against degradation by 
various enzymes
2,3
. Influenza virus NP 
characteristically has a nuclear localization signal 
(NLS) and an RNA-binding domain. Influenza virus 
nucleoprotein (NP) is more conserve than its 
membrane glycoproteins
4,5
. Although the NP induces 
an antibody response. Horimoto et al. (2005), in a 
study conducted on influenza pandemics, found out 
that the nucleoprotein induces a CD8
+
 T-cell response 
which may contribute to resistance against severe 
disease following influenza A virus infection
2
. 
According to Ruan (2012) recombinant influenza 
nucleoprotein can induce specific antibodies and T cell 
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responses in mice
6
. So our purpose in present 
research was to produce the sufficient recombinant 
NP in the E. coli host. 
Methods 
The preparation of the NP gene construct 
1500 bases nucleotide sequences of the influenza 
H1N1 NP (A/Shiraz/14/2010) was obtained from the 
NCBI. According to the available data, the NP gene 
was considered for codon optimization using the 
Encorbio website: 
(www.encorbio.com/protocols/codon.htm), and then 
it was artificially synthesized (MWG,Germany) and 
inserted into a pGE plasmid.  
To sub- cloning of NP gene into expression vector, it 
was digested with NotI and HindIII (Fermentas, 
Lithuania) restriction enzymes. The digestion product 
was analyzed by electrophoresis on 1.5% agarose gel 
and the desired band was removed and purified by 
DNA gel extraction kit (Qiagene, USA). The purified 
fragment was inserted into digested pET22b vector 
(Pasteur, Iran) and transformed into E. coli Top 10 
strain. Recombinant plasmid was extracted by 
plasmid extraction kit (Qiagene, USA). The 
recombinant plasmid was confirmed by PCR analysis 
using universal primers and also digestion by NotI 
and HindIII restriction enzymes
7
.  
The expression of the NP protein 
Extracted recombinant plasmids were transformed 
into E. coli BL21 by Hanahan method. Overnight 
incubated colonies were inoculated in LB broth. 
Cultures in the logarithmic phase (at OD600 of 0.6) 
were induced for 6 hour with 1 mM, IPTG (Isopropyl 
β-D-1-thiogalactopyranoside). After induction cells 
were lysed in 5x sample buffer [100 mM Tris HCl 
pH 8, 20% (w/v) glycerol, 4% (w/v) SDS, 2% (w/v) 
beta-mercaptoethanol, 0.2% (v/v) bromo phenol 
blue] (sigma) and analyzed on 12% (v/v) SDS-
PAGE. The resulting gel was stained with coomassie 
brilliant blue R-250. The uninduced control culture 
was analyzed in parallel
7
.  
The western blot analysis   
Result of SDS-PAGE was confirmed by western 
blotting using Anti-His Tag polyclonal antibody as 
the primary antibody and anti-mouse HRP 





NP gene construct confirmation 
The 1500 bases NP gene was extracted from pGE 
vector and ligated into pET-22b expression vector. 
The recombinant plasmid and NP gene (1500 bases) 
after digestion have been shown in figure 1. Figure 2 
shows analysis of new construct by PCR reaction. 
NP recombinant protein expression 
The expression of recombinant influenza 
nucleoprotein in E. coli BL21 (DE3) was detected and 
compared with control bacteria by SDS PAGE 
analysis which was shown in figure 3.  
The confirmation of protein expression by western 
blot analysis 
The result of expressed band was confirmed by 
western blotting. The brown band for positive 




Figure 1. Restriction analysis of pET22b/NP by NotI and 
HindIII; Lane 1: undigested recombinant plasmid, Lane 2:  




Figure 2. Confirmation of pET22b/NP by PCR; Lane 1:1700bp 
PCR product of cloned plasmid, Lane 2: 200bp PCR product of 
intact plasmid, Lane 3:100 bp DNA ladder. 
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Discussion 
The purpose of the study was to develop of Influenza 
H1N1 recombinant nucleoprotein production. 
Influenza viruses cause highly contagious respiratory 
diseases with potentially fatal outcomes
9
. Pandemic 
influenza represented a major threat to global public 
health. The results of this study showed that pET-22b 
expression vector and induction with IPTG were the 
appropriate condition for influenza NP production. 
The NP gene is highly conserved compared with the 
other genes of virus
10
. Influenza A nucleoprotein 
(NP), the major protein component of 
ribonucleoprotein (RNP) complexes, is also 
relatively conserved making it an attractive candidate 
for a universal flu vaccine
1
. By attention to 
mentioned issues in this study, the codon optimized 
recombinant nucleoprotein (rNP) of H1N1 influenza 
virus of Iran isolate strain was sufficiently expressed 
using a pET expression system. Most amino acids are 
encoded by more than one codon and each organism 
carries the 61 available amino acid codons. Studies of 
the genomes of a wide variety of organisms have 
revealed a correlation between gene expression level 
and codon usage bias, namely that high gene 
expression leads to high bias
11
. So the set up condition 
is proper to express the influenza NP gene in BL21 
(DE3) plysS E. coli host. 
Also Salahuddin and Khan’s study
12
 showed that 
mutations in essential functional regions of conserved 
influenza NP and NS1proteins lead to reduced 
expression of these genes in vitro. Therefore, distinct 
internal secondary structures of viral mRNA may be 
important for viral gene expression. Finally, 
introducing mutations in viral genes while preserving 
their secondary RNA structure, suggests a new method 




The protective vaccines against all influenza A viruses 
might substantially reduce severity of infection and 
limit spread of disease during outbreaks
9
. It is 
recommended that the design of a multi conserved 
domains protein against of Influenza is a necessary 
thing in the world. 
Conclusion 
In the present study we tried to express NP 
recombinant protein of influenza A H1N1 virus 
(A/Shiraz/14/2010 strain) in order to provide 
preventive strategies for the Iranian population. In the 
present research a 50 KD band was observed which is 
in agreement with previous studies. Based on the 
results of this study, it could be concluded that the NP 
gene of the influenza A H1N1 virus (A/Shiraz/14/2010 
strain), could be cloned and the rNP (recombinant NP) 
could be expressed using the bacterial protein 
translation system. Since this protein is a conservative 
protein among influenza A viruses, it can be used as a 
potent vaccine for the prevention of various types of 
pandemics caused by influenza A. 
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Figure 3. Comparison between protein expressions in different 
times after induction; Lane 1: lysate of bacterial cell content pET-
22b, Lane 2: lysate of Host cell (control), Lane 3: lysate of 
expressed recombinant bacteria 5 hours after induction by IPTG. 
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